Concord Drugs Share Price
74.00-1.30 (-1.73%)
+8.82% past 1 Year
Corporate filings & documents
Announcements
Copies of News paper publications of the Notice of the 31st AGM to be held on 30.09.2026
1 week agoCopies of News paper publications of the Notice of the 31st AGM to be held on 30.09.2026
1 week agoLetter to members as per regulation 36(1)(b)
1 week agoLetter to members as per regulation 36(1)(b)
1 week agoRecord date for Annual general meeting
1 week agoRecord date for Annual general meeting
1 week agoBook Closure for AGM to be held on 30.09.2026
1 week agoBook Closure for AGM to be held on 30.09.2026
1 week ago31st Annual Report of the Company
1 week ago31st Annual Report of the Company
1 week agoAGM to be held on 30.09.2026 at 09:00 AM
1 week agoAGM to be held on 30.09.2026 at 09:00 AM
1 week agoCompany has approved the notice and proposed to hold 31st AGM on 30.09.2026
1 week agoCompany has approved the notice and proposed to hold 31st AGM on 30.09.2026
1 week agoCopy of News-paper publications for quarterly results ended 30th June 2026.
1 month agoCopy of News-paper publications for quarterly results ended 30th June 2026.
1 month agoBoard of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026
1 month agoBoard of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026
1 month agoOutcome of Board meeting
1 month agoOutcome of Board meeting
1 month agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 inter alia to consider and approve Quarterly Results
1 month agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 inter alia to consider and approve Quarterly Results
1 month agoCertificate under Reg 74(5) of SEBI (DP) Regulations
2 months agoCertificate under Reg 74(5) of SEBI (DP) Regulations
2 months agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoCopy of Newspaper publication for audited results for year ended 31st March 2026.
3 months agoCopy of Newspaper publication for audited results for year ended 31st March 2026.
3 months agoAnnual Secretarial Compliance report under Regulation 24(A)
3 months agoFinancial Results for Year ending 31st March 2026
3 months agoCompany has approved financial results for Quarter and year ending 31st March 2026
3 months agoCompany in its Board Meeting has approved financial results for period ended 31st March 2026
3 months agoCompany in its Board Meeting has approved financial results for period ended 31st March 2026
3 months agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Financial Results for year ending 31.03.2026
4 months agoConcord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Financial Results for year ending 31.03.2026
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 06/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 06/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Reg 74(5)
5 months agoCertificate under Reg 74(5)
5 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Concord Drugs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230TG1995PLC020093</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Namratha Nagla</td></tr><tr><td>Designation :-</td><td>Compliance officer and Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>koni Reddy seelam</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 10/04/2026<br/><br/></div>
5 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Concord Drugs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230TG1995PLC020093</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Namratha Nagla</td></tr><tr><td>Designation :-</td><td>Compliance officer and Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>koni Reddy seelam</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 10/04/2026<br/><br/></div>
5 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>10.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 10/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months agoClosure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March 2026.
5 months agoClosure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March 2026.
5 months agoNews Paper publication of Q3 results
7 months agoNews Paper publication of Q3 results
7 months agoGeneral Update
7 months agoGeneral Update
7 months agoUn-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec 2025.
7 months agoUn-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec 2025.
7 months agoAnnual reports
Concalls & investor presentations
No presentations found